Edgewise Therapeutics
Open
$30.50
Prev. Close
$30.50
High
$30.54
Low
$30.50
Market Snapshot
$3.22B
-19.2
-1.45
146
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 146 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
emptyResult
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 146 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Recently from Cashu
Edgewise Therapeutics Appoints New Leadership to Propel Cardiovascular Pipeline Growth
Edgewise Therapeutics Strengthens Leadership to Advance Cardiovascular Pipeline Edgewise Therapeutics, Inc. announces a transformative shift in its executive leadership aimed at enhancing the company'…
Edgewise Therapeutics Advances Treatments for Muscle Diseases with Promising Drug Pipeline
Edgewise Therapeutics Charts a Path Forward in Muscle Disease Treatment Edgewise Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape, particularly in the treatment of m…
Edgewise Therapeutics: Innovating Treatments for Muscle Diseases and Cardiac Disorders
Edgewise Therapeutics: Pioneering Innovations in Muscle Disease Treatment Edgewise Therapeutics, Inc., a key player in the biopharmaceutical landscape, focuses on developing groundbreaking treatments…
Edgewise Therapeutics to Present Muscle Disease Innovations at Piper Sandler Healthcare Conference
Edgewise Therapeutics Showcases Commitment to Muscle Disease Innovation at Upcoming Healthcare Conference Edgewise Therapeutics, Inc., a biopharmaceutical leader focused on muscle diseases, is set to…